pharmaceutical-investing AMAG Pharmaceuticals Announces Topline Results From the PROLONG Trial Evaluating Makena
pharmaceutical-investing AMAG Pharmaceuticals Acquires Orphan Drug Candidate for Treatment of Severe Preeclampsia
pharmaceutical-investing AMAG Pharmaceuticals Submits a New Drug Application to the U.S. Food and Drug Administration
pharmaceutical-investing AMAG Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for Feraheme
pharmaceutical-investing AMAG and Endoceutics Enter Into an Exclusive U.S. License Agreement for Intrarosa™ (Prasterone)
pharmaceutical-investing AMAG Pharmaceuticals Announces Closing of Exclusive Licensing Agreement for North American Rights to Rekynda™
AMAG Pharmaceuticals Announces Achievement of Key Milestones in Next Generation Development Programs for Makena® and Feraheme®
